PARD (Poniard Pharmaceuticals) YoY EBITDA Growth: 50.80% (As of Sep. 2011)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Poniard Pharmaceuticals YoY EBITDA Growth?

Poniard Pharmaceuticals PARD YoY EBITDA Growth is 50.80% as of Sep. 2011.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Poniard Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Sep. 2011 was 50.80%.

Poniard Pharmaceuticals's EBITDA per Share for the three months ended in Sep. 2011 was $-2.29.

Poniard Pharmaceuticals YoY EBITDA Growth Related Terms

Poniard Pharmaceuticals YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Poniard Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poniard Pharmaceuticals YoY EBITDA Growth Chart

Poniard Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.60 -13.43 -23.26 19.45 51.68

Poniard Pharmaceuticals Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.19 68.43 75.14 50.25 50.80

Poniard Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Poniard Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2010 is calculated as:

YoY EBITDA Growth (A: Dec. 2010 )
=(EBITDA per Share (A: Dec. 2010 )-EBITDA per Share (A: Dec. 2009 ))/ | EBITDA per Share (A: Dec. 2009 ) |
=(-21.347--44.18)/ | -44.18 |
=51.68 %

Poniard Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Sep. 2011 is calculated as:

YoY EBITDA Growth (Q: Sep. 2011 )
=(EBITDA per Share (Q: Sep. 2011 )-EBITDA per Share (Q: Sep. 2010 )) / | EBITDA per Share (Q: Sep. 2010 )) |
=(-2.294--4.663)/ | -4.663 |
=50.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 50.80% mean?
Poniard Pharmaceuticals (PARD) has a YoY EBITDA Growth of 50.80% as of Sep. 2011. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Poniard Pharmaceuticals and its competitors.
Is Poniard Pharmaceuticals' YoY EBITDA Growth too high?
Poniard Pharmaceuticals' current YoY EBITDA Growth is 50.80%.
How does Poniard Pharmaceuticals' YoY EBITDA Growth compare to OBMP and NSPX?
Poniard Pharmaceuticals' YoY EBITDA Growth of 50.80% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Poniard Pharmaceuticals and its competitors. Poniard Pharmaceuticals's current YoY EBITDA Growth is 50.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poniard Pharmaceuticals stock overvalued right now?
Poniard Pharmaceuticals (PARD) has a current YoY EBITDA Growth of 50.80%. The current YoY EBITDA Growth is 50.80%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Poniard Pharmaceuticals (PARD), the current YoY EBITDA Growth is 50.80% as of Sep. 2011. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poniard Pharmaceuticals Business Description

Address 300 Elliott Avenue West, Suite 530, Seattle, CA, USA, 98119
Poniard Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of cancer therapeutics. Its product candidate is picoplatin, a new generation platinum-based cancer therapy.